Pulmonary Hypertension in Acute and Chronic High Altitude Maladaptation Disorders
Top Cited Papers
Open Access
- 10 February 2021
- journal article
- review article
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 18 (4), 1692
- https://doi.org/10.3390/ijerph18041692
Abstract
Alveolar hypoxia is the most prominent feature of high altitude environment with well-known consequences for the cardio-pulmonary system, including development of pulmonary hypertension. Pulmonary hypertension due to an exaggerated hypoxic pulmonary vasoconstriction contributes to high altitude pulmonary edema (HAPE), a life-threatening disorder, occurring at high altitudes in non-acclimatized healthy individuals. Despite a strong physiologic rationale for using vasodilators for prevention and treatment of HAPE, no systematic studies of their efficacy have been conducted to date. Calcium-channel blockers are currently recommended for drug prophylaxis in high-risk individuals with a clear history of recurrent HAPE based on the extensive clinical experience with nifedipine in HAPE prevention in susceptible individuals. Chronic exposure to hypoxia induces pulmonary vascular remodeling and development of pulmonary hypertension, which places an increased pressure load on the right ventricle leading to right heart failure. Further, pulmonary hypertension along with excessive erythrocytosis may complicate chronic mountain sickness, another high altitude maladaptation disorder. Importantly, other causes than hypoxia may potentially underlie and/or contribute to pulmonary hypertension at high altitude, such as chronic heart and lung diseases, thrombotic or embolic diseases. Extensive clinical experience with drugs in patients with pulmonary arterial hypertension suggests their potential for treatment of high altitude pulmonary hypertension. Small studies have demonstrated their efficacy in reducing pulmonary artery pressure in high altitude residents. However, no drugs have been approved to date for the therapy of chronic high altitude pulmonary hypertension. This work provides a literature review on the role of pulmonary hypertension in the pathogenesis of acute and chronic high altitude maladaptation disorders and summarizes current knowledge regarding potential treatment options.Funding Information
- Deutsche Forschungsgemeinschaft (268555672 – CRC1213 Project A09)
- Cardiovascular Medical Research and Education Fund (N/A)
- Ministry of education and science of the Kyrgyz Republic (0005823)
This publication has 358 references indexed in Scilit:
- Cardiopulmonary function in two human disorders of the hypoxia‐inducible factor (HIF) pathway: von Hippel‐Lindau disease and HIF‐2α gain‐of‐function mutationThe FASEB Journal, 2011
- Hypoxia-induced changes in pulmonary and systemic vascular resistance: Where is the O2 sensor?Respiratory Physiology & Neurobiology, 2010
- High-altitude pulmonary hypertension is associated with a free radical-mediated reduction in pulmonary nitric oxide bioavailabilityJournal Of Physiology-London, 2010
- Rosiglitazone Attenuates Chronic Hypoxia–Induced Pulmonary Hypertension in a Mouse ModelAmerican Journal of Respiratory Cell and Molecular Biology, 2010
- The von Hippel–Lindau Chuvash mutation promotes pulmonary hypertension and fibrosis in miceJCI Insight, 2010
- Notch3 signaling promotes the development of pulmonary arterial hypertensionNature Medicine, 2009
- Sustained hypoxia promotes the development of a pulmonary artery-specific chronic inflammatory microenvironmentAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2009
- The increase in pulmonary arterial pressure caused by hypoxia depends on iron statusJournal Of Physiology-London, 2008
- Higher blood flow and circulating NO products offset high-altitude hypoxia among TibetansProceedings of the National Academy of Sciences of the United States of America, 2007
- Classical transient receptor potential channel 6 (TRPC6) is essential for hypoxic pulmonary vasoconstriction and alveolar gas exchangeProceedings of the National Academy of Sciences of the United States of America, 2006